US voucher worth up to $200m pulls rare-disease money west
The FDA's Priority Review Voucher scheme was signed back into law in February. UK rare-disease founders have no equivalent, and one of them says investors notice.
Developers of rare paediatric disease treatments in the United States can earn a tradable voucher that speeds up a future drug review. Recent sales have gone for between $150 million and $200 million.
A sale does not require the seller to issue new equity. That makes the voucher a source of capital that costs the founder no ownership.
The Rare Pediatric Disease Priority Review Voucher programme was signed back into law in February. It runs until it is reviewed again in September 2029.
Investment in rare disease biotechs has risen since then, according to SynaptixBio, though the company says the United States remains dominant. SynaptixBio is the only company licensed to commercialise a treatment for H-ABC, a rare and deadly disease.
"The US dominates because the PRV program creates a highly valuable and, more importantly, tradable asset," said Dan Williams, chief executive of SynaptixBio. He said venture capital and private equity firms are more willing to back rare disease biotechs because they offer a financial return.
The VC firm V-Bio said reauthorisation of the scheme had restored financial certainty and sparked intense interest from large pharma.
Williams said the UK has seen a sharp contraction in biotech fundraising, and that without an equivalent to the PRV scheme, UK rare disease biotechs depend on public markets, private investment or acquisition by a larger global pharma company.
The Association of the British Pharmaceutical Industry warned last September that the UK was slipping in the global race for life sciences investment, with foreign direct investment 58 per cent below 2017 levels.
There are counter-signals. Figures from the data platform Tracxn show UK life sciences funding rose 228 per cent to $3.2 billion in the first half of 2026, though the money went to fewer companies.
Analysis published by Schroders in April said UK companies have too often been forced to list in New York to reach the depth of capital needed to fund clinical trials, describing the gap between seed-stage science and trial financing as the sector's long-standing weakness.
The regulatory side is moving. The Medicines and Healthcare products Regulatory Agency published a draft framework for rare disease therapies in May, intended to get such drugs to market faster. The consultation closed on 30 July.
Williams said the framework would improve management of trials and marketing authorisation, but stops there, and that an incentive on the American model could transform the industry. He said SynaptixBio still aims to run clinical trials in the UK and use the results to inform later trials in the US, subject to raising further investment.
SynaptixBio selected its lead candidate last year, an antisense oligonucleotide that silences mutated genes so they stop forming toxic proteins, without editing the gene itself.
The addressable problem is large. Around one in 17 people will be affected by a rare disease in their lifetime, more than 3.5 million people in the UK, yet only about 5 per cent of the roughly 10,000 known rare diseases have an approved treatment. Around 80 per cent are caused by a mutation in a single gene.
For a founder weighing where to incorporate or where to run a first trial, the maths is blunt: a US-eligible programme carries a potential asset worth up to $200 million that dilutes nobody. A UK-only programme carries faster approvals and no such asset. That gap is now fixed until at least September 2029.